Routes of
administration Oral Legal status Development terminated CAS Number 877130-28-4 Molar mass 503.636 g/mol | ATC code none Synonyms PF-00868554 PubChem CID 54708673 | |
 | ||
How to pronounce filibuvir
Filibuvir (also known as PF-00868554, PF-868554) was a non-nucleoside orally available NS5B inhibitor developed by Pfizer for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases. Several filibuvir-resistant mutations have been identified, M423 being the most common that occurred after filibuvir monotherapy. It was intended to be taken twice-daily.
Its investigation was discontinued on February 2013 due to strategic reasons.
References
Filibuvir Wikipedia(Text) CC BY-SA